Skip to content
Subscriber Only

Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

It’s a make or break year for GlaxoSmithKline Plc. The U.K.’s largest pharmaceutical company is counting on a spate of drugs winning approval this year to reverse recent setbacks and revive growth.

Glaxo needs some wins. Its shares fell 9.3 percent in 2012, compared with an 11 percent increase in the Bloomberg Europe Pharmaceutical Index. With five new medicines submitted to regulators for approval and another in the works, help is on the way, according to a top executive.